1. Home
  2. HXHX vs ABP Comparison

HXHX vs ABP Comparison

Compare HXHX & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HXHX

Haoxin Holdings Limited Class A Ordinary Shares

HOLD

Current Price

$0.51

Market Cap

12.0M

Sector

Industrials

ML Signal

HOLD

ABP

Abpro Holdings Inc

HOLD

Current Price

$3.50

Market Cap

12.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HXHX
ABP
Founded
2003
2004
Country
China
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0M
12.5M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
HXHX
ABP
Price
$0.51
$3.50
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
17.4M
10.7K
Earning Date
02-18-2026
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
1.80
N/A
EPS
0.30
N/A
Revenue
$34,088,144.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.69
N/A
Revenue Growth
32.57
50.00
52 Week Low
$0.33
$3.56
52 Week High
$6.29
$42.90

Technical Indicators

Market Signals
Indicator
HXHX
ABP
Relative Strength Index (RSI) 43.88 32.76
Support Level $0.47 $3.82
Resistance Level $0.62 $4.11
Average True Range (ATR) 0.10 0.40
MACD -0.01 -0.08
Stochastic Oscillator 5.73 5.93

Price Performance

Historical Comparison
HXHX
ABP

About HXHX Haoxin Holdings Limited Class A Ordinary Shares

Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.

About ABP Abpro Holdings Inc

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.

Share on Social Networks: